Charles Riv Labs Intl Inc - CRL STOCK NEWS

Charles River Laboratories (NYSE: CRL) has announced updates to its oncology drug discovery and development portfolio, highlighting its work on over 80% of FDA-approved cancer therapies in the past five years. The company is expanding its in vitro assays using fully human platforms to enhance therapeutic development.

Key technological advancements include:

• Development of PDX-derived organoids (tumoroids) for more translatable 3D cell cultures
• Implementation of immune-mediated tumor-killing assays
• Enhanced tumor microenvironment targeting capabilities through partnership with Cypre
• Expansion of humanized mice models
• Integration of AI/ML tools through collaborations with Revvity and Aitia

The company offers over 200 RACE Act-compliant pediatric PDX models through the ITCC-P4 consortium, supporting mandatory pediatric testing for oncology drugs. This initiative addresses the critical need for pediatric cancer treatments, as 400,000 children develop cancer annually worldwide, with 25% lacking effective treatment options.

Charles River Laboratories (NYSE: CRL) has announced it will release its first-quarter 2025 financial results on Wednesday, May 7th, before market opening. The company has scheduled a conference call at 9:00 a.m. ET on the same day to discuss the quarterly results. Investors can access the live webcast through the Investor Relations section at ir.criver.com, where a replay will also be available.

Charles River Laboratories (NYSE: CRL) has announced its upcoming presentation at the Barclays 27th Annual Global Healthcare Conference scheduled for Wednesday, March 12th, at 9:30 a.m. ET.

During the presentation, management will provide insights into the company's:

• Strategic focus
• Business developments
• Recent trends

Investors and interested parties can access a live webcast of the presentation through the Investor Relations section at ir.criver.com. A replay will be available on the same platform for a minimum of two weeks following the presentation.

Charles River Laboratories (NYSE: CRL) has entered an agreement with Singapore General Hospital (SGH) to provide CGMP-compliant master cell banking and next-generation sequencing (NGS) services. These services will aid in the characterization of cell lines derived from cord blood for allogeneic CAR-T cell production, aimed at treating cancer patients.

SGH will utilize Charles River's CGMP master cell banking services and NGS-based testing for their upcoming Phase I clinical trials. The NGS technology offers high throughput, scalability, and speed, revolutionizing genetic analysis and pathogen detection. It provides a more efficient and reliable testing option compared to traditional animal-based testing.

Charles River's services ensure compliance with GMP, FDA, EMA, and ICH Q5A and Q5B standards, accelerating development timelines without compromising safety. The company offers a full range of CGMP-compliant cell bank production and storage services, including 9 ISO-6 cleanroom suites and a cell bank completion to release timeline of 8-10 weeks.

Charles River Laboratories reported Q4 2024 revenue of $1.00 billion, down 1.1% from Q4 2023, and full-year 2024 revenue of $4.05 billion, a 1.9% decrease from 2023. The company posted a Q4 GAAP loss per share of $(4.22), primarily due to a $215.0 million non-cash goodwill impairment related to the Biologics Solutions unit.

Full-year 2024 GAAP earnings were $0.20 per share, while non-GAAP earnings reached $10.32 per share. The company's organic revenue declined by 2.8% in 2024. For 2025, Charles River projects an organic revenue decrease of 3.5% to 5.5% and non-GAAP EPS of $9.10 to $9.60.

The company announced plans for $350 million in stock repurchases for 2025. Management noted continued constraints in early-stage spending by global biopharmaceutical clients, while expecting stable to slightly improved demand from small and mid-sized biotechnology clients.

Charles River Laboratories (NYSE: CRL) and Deciphex have announced an expansion of their strategic partnership to advance digital pathology solutions. The collaboration focuses on integrating the Patholytix platform across Charles River's global network to enhance image management, distribution, and archiving workflows in toxicologic pathology.

Building on their successful 2024 launch of Foresight, the partnership aims to develop advanced AI tools for toxicologic pathology, including new screening capabilities for acute toxicity and carcinogenicity studies. The integrated system is expected to streamline digital workflows, reduce turnaround times, and enable better collaboration across global teams.

The partnership combines Deciphex's digital pathology expertise with Charles River's toxicologic pathology network, offering clients enhanced capabilities for primary evaluation and peer review in toxicologic pathology assessment, ultimately accelerating drug development and safety assessment processes.

Charles River Laboratories (NYSE: CRL) has announced it will release its fourth-quarter and full-year 2024 financial results along with 2025 guidance on Wednesday, February 19th, before market opening. The company has scheduled a conference call at 8:30 a.m. ET on the same day to discuss these results.

Investors can access a live webcast of the conference call through the Investor Relations section of the company's website at ir.criver.com. A replay of the call will also be made available through the same platform.

Charles River Laboratories (NYSE: CRL) announced the launch of Apollo™ for CRADL®, a secure cloud-based platform enhancing their vivarium rental services. The platform streamlines research initiation by providing a centralized dashboard connecting clients to online training, research models ordering, and study support services.

Apollo serves as the technology stack driving Charles River's digital transformation, offering expanded client access across their portfolio through multiple integrations:

• Apollo for CRADL: Streamlines administrative tasks for vivarium rental solutions
• Apollo for Safety Assessment: Provides real-time access to data visualization and program planning
• Apollo for Biologics: Centralizes sample submission and tracking
• Apollo for Discovery: Enables instant oncology study price estimates
• Apollo for Logica®: Delivers real-time updates for AI-powered small molecule programs
• Research Models Online Ordering System: Offers interactive catalog with real-time inventory

Charles River Laboratories (NYSE: CRL) and Akron Bio announced the integration of Akron's Closed System Solutions (CSS)™ line of liquid cytokines into Charles River's Cell Therapy Flex Platform for Process Development. This integration aims to enhance closed system processing, streamline operations, and improve process robustness.

The Cell Therapy Flex Platform, designed as an off-the-shelf solution for Cell Therapy Process Development, now incorporates Akron's CGMP liquid cytokines, including rHu IL-2, IL-7, IL-15, and IL-21. These cytokines are available in single-use bags with weldable tubing, maintaining stability at 2-8°C and enabling rapid, aseptic media formulation while minimizing operator error.

This collaboration enhances manufacturing efficiency by decreasing labor requirements and improving process robustness for CAR-T and TCR-T cell therapies development.